To include your compound in the COVID-19 Resource Center, submit it here.

Ivabradine: Phase III data

In May, EMA's Pharmacovigilance Risk Assessment Committee began a safety review of the drug based on preliminary SIGNIFY data. The committee is expected to make final recommendations to EMA's CHMP in November. Servier markets ivabradine as Procoralan in at least 100

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers